Evidence map›Paper›PMID 19033423›Full record

ArticleNeuro-oncology2009

Lactate promotes glioma migration by TGF-beta2-dependent regulation of matrix metalloproteinase-2.

Fusun Baumann, Petra Leukel, Anett Doerfelt, Christoph P Beier, Katja Dettmer, Peter J Oefner, Michael Kastenberger, Marina Kreutz, Thomas Nickl-Jockschat, Ulrich Bogdahn and 2 more

Registry-linked trialOpen access · greenAbstract read
In one paragraph

Article in Neuro-oncology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07450833 (Assessing the Safety, Tolerability and Pharmacokinetics of Benfo-Oxythiamine), which is not on this map. Cited by 143 papers.

0numbers the graph read from it
0cells of the map it votes in
143citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07450833 phase1completednot on this mapstarted 2022, after this paper: background citation

Assessing the Safety, Tolerability and Pharmacokinetics of Benfo-Oxythiamine (B-OT) in Healthy Volunteers - An Open Label, Phase I Study

TypeinterventionalSponsorBenfovir AGRan2022 to 2022Enrolled48ConditionsHealthy VolunteersArmsBenfo-oxythiamine
3 · Its place in the literature

Who cites it

143 citing papers in PubMed, 251 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Lactate, a Spearhead of Cancer Aggressiveness: Metabolic Reprogramming, Immune Suppression, and Metastatic Progression.Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2026
    Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Review

83 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

Fusun BaumannDepartment of Neurology, University of Regensburg, Universitätsstrasse 84, 93053 Regensburg, Germany.
Petra Leukel
Anett Doerfelt
Christoph P Beier
Katja Dettmer
Peter J Oefner
Michael Kastenberger
Marina Kreutz
Thomas Nickl-Jockschat
Ulrich Bogdahn
Anja-Katrin Bosserhoff
Peter Hau
University of Regensburg · DEUniversity Hospital Regensburg · DERWTH Aachen University · DERoyal Brisbane and Women's Hospital · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lactate dehydrogenase type A (LDH-A) is a key metabolic enzyme catalyzing pyruvate into lactate and is excessively expressed by tumor cells. Transforming growth factor-beta2 (TGF-beta2) is a key regulator of invasion in high-grade gliomas, partially by inducing a mesenchymal phenotype and by remodeling the extracellular matrix. In this study, we tested the hypothesis that lactate metabolism regulates TGF-beta2-mediated migration of glioma cells. Small interfering RNA directed against LDH-A (siLDH-A) suppresses, and lactate induces, TGF-beta2 expression, suggesting that lactate metabolism is strongly associated with TGF-beta2 in glioma cells. Here we demonstrate that TGF-beta2 enhances expression, secretion, and activation of matrix metalloproteinase-2 (MMP-2) and induces the cell surface expression of integrin alpha(v)beta(3) receptors. In spheroid and Boyden chamber migration assays, inhibition of MMP-2 activity using a specific MMP-2 inhibitor and blocking of integrin alpha(v)beta(3) abrogated glioma cell migration stimulated by TGF-beta2. Furthermore, siLDH-A inhibited MMP2 activity, leading to inhibition of glioma migration. Taken together, we define an LDH-A-induced and TGF-beta2-coordinated regulatory cascade of transcriptional regulation of MMP-2 and integrin alpha(v)beta(3). This novel interaction between lactate metabolism and TGF-beta2 might constitute a crucial mechanism for glioma migration.

Indexed as

Cell MovementBrain NeoplasmsEnzyme-Linked Immunosorbent AssayFlow CytometryGene Expression Regulation, NeoplasticGliomaGlucoseHumansIntegrin alphaVbeta3IsoenzymesLactate Dehydrogenase 5L-Lactate DehydrogenaseMatrix Metalloproteinase 2Matrix Metalloproteinase InhibitorsReverse Transcriptase Polymerase Chain ReactionRNA, MessengerGlucoseIntegrin alphaVbeta3IsoenzymesLactate Dehydrogenase 5L-Lactate DehydrogenaseMatrix Metalloproteinase 2Matrix Metalloproteinase InhibitorsRNA, MessengerRNA, Small InterferingTGFB2 protein, humanTransforming Growth Factor beta2

Identifiers

PMID19033423
PMCPMC2743217
OpenAlexW2064972175

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.